Pharmaceutical Industry Raises Doubts on Bio-Equivalent Test
Published: 2001-08-17 06:59:00
Updated: 2001-08-17 06:59:00
The pharmaceutical industry has issued a strong opinion regarding the bio-equivalent test, saying that its implementation only for the sale of substitutable dispensation without any consideration of the economic factors should be restrained.
The KFDA has been receiving the requisition for the ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
